AU2008216799A1 - Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa - Google Patents

Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa Download PDF

Info

Publication number
AU2008216799A1
AU2008216799A1 AU2008216799A AU2008216799A AU2008216799A1 AU 2008216799 A1 AU2008216799 A1 AU 2008216799A1 AU 2008216799 A AU2008216799 A AU 2008216799A AU 2008216799 A AU2008216799 A AU 2008216799A AU 2008216799 A1 AU2008216799 A1 AU 2008216799A1
Authority
AU
Australia
Prior art keywords
mucositis
day
days
scv
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008216799A
Other languages
English (en)
Inventor
Israel Rios
Cynthia Tuthill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of AU2008216799A1 publication Critical patent/AU2008216799A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008216799A 2007-02-13 2008-02-11 Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa Abandoned AU2008216799A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90097707P 2007-02-13 2007-02-13
US60/900,977 2007-02-13
PCT/US2008/001768 WO2008100458A2 (en) 2007-02-13 2008-02-11 Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa

Publications (1)

Publication Number Publication Date
AU2008216799A1 true AU2008216799A1 (en) 2008-08-21

Family

ID=39690681

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008216799A Abandoned AU2008216799A1 (en) 2007-02-13 2008-02-11 Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa

Country Status (14)

Country Link
US (2) US7906486B2 (OSRAM)
EP (1) EP2120986A4 (OSRAM)
JP (1) JP2010518160A (OSRAM)
KR (1) KR20090119897A (OSRAM)
CN (1) CN101657210A (OSRAM)
AR (1) AR065338A1 (OSRAM)
AU (1) AU2008216799A1 (OSRAM)
CA (1) CA2677749A1 (OSRAM)
IL (1) IL200364A0 (OSRAM)
MX (1) MX2009008641A (OSRAM)
NZ (1) NZ579570A (OSRAM)
TW (1) TW200845958A (OSRAM)
UA (1) UA96980C2 (OSRAM)
WO (1) WO2008100458A2 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2677749A1 (en) * 2007-02-13 2008-08-21 Sciclone Pharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa
RU2436587C1 (ru) * 2010-10-21 2011-12-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") N-изовалероил-l-глутамил-l-триптофан как средство, препятствующее язвообразованию в желудке и двенадцатиперстной кишке
CN109528202B (zh) * 2018-11-14 2021-07-16 北京大学第一医院 一种头颈部放疗诊疗系统

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125626A (en) * 1977-01-17 1978-11-14 Mt. Sinai School Of Medicine Of The City University Of New York Synthesis and use of L-γ-glutamyl-DOPA
US4568489A (en) * 1984-06-29 1986-02-04 E. R. Squibb & Sons, Inc. N-Acyl-γ-glutamyl imino and amino acids and esters
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4758551A (en) * 1986-07-08 1988-07-19 Cornell Research Foundation, Inc. Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US4895835A (en) * 1987-11-20 1990-01-23 Nisshin Oil Mills, Ltd. Muramyl peptide derivatives and use thereof
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5902790A (en) * 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
US5206220A (en) * 1990-04-23 1993-04-27 Research Corporation Technologies, Inc. Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition
WO1992017191A1 (en) 1991-04-01 1992-10-15 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
WO1993008815A1 (en) 1991-10-28 1993-05-13 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
WO1994020063A2 (en) 1993-03-04 1994-09-15 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
GB9320820D0 (en) * 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
RU2107692C1 (ru) * 1995-06-07 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
RU2120298C1 (ru) 1995-11-28 1998-10-20 Товарищество с ограниченной ответственностью "Верта" Иммуностимулятор и препарат на его основе
WO1997019691A1 (en) 1995-11-28 1997-06-05 Wei, Edward, T. Gamma-l-glutamyl containing immunomodulator compounds and methods therewith
US6060452A (en) * 1996-03-13 2000-05-09 Cytran, Inc. Analogs of L-Glu-L-Trp having pharmacological activity
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
US7173013B2 (en) * 2001-06-08 2007-02-06 Sciclone Pharmaceuticals, Inc. Treatment of tuberculosis using immunomodulator compounds
RU2229892C2 (ru) 2001-06-08 2004-06-10 Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" Способ лечения туберкулеза легких
US20050256042A1 (en) * 2003-05-09 2005-11-17 Jeffers Michael E Methods of preventing and treating alimentary mucositis
AU2005244826B2 (en) * 2004-05-14 2010-07-29 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with immunomodulator compounds
JP4874985B2 (ja) 2004-10-27 2012-02-15 サイクローン・ファーマシューティカルズ・インコーポレイテッド 免疫調節化合物による出血性ウイルス感染の治療又は予防
WO2006076169A2 (en) 2004-12-28 2006-07-20 Sciclone Pharmaceuticals, Inc. Treatment or prevention of genital viral infections with immunomodulator compounds
US20090074815A1 (en) * 2005-04-22 2009-03-19 Sciclone Pharmaceuticals, Inc. Immunomodulator Compounds as Vaccine Enhancers
AU2007240946A1 (en) * 2006-04-20 2007-11-01 Sciclone Pharmaceuticals, Inc. Treatment of melanoma
JP2010513508A (ja) 2006-12-18 2010-04-30 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｃ型肝炎感染を処置するための併用療法
CA2677749A1 (en) * 2007-02-13 2008-08-21 Sciclone Pharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa
RU2007118237A (ru) 2007-05-17 2008-11-27 ООО "Научно-производственна фирма Верта" (RU) Способ лечения аллергических заболеваний
US20110189305A1 (en) 2007-08-23 2011-08-04 Tuthill Cynthia W Treatment of lung cancer
JP2011530519A (ja) 2008-08-06 2011-12-22 サイクローン・ファーマシューティカルズ・インコーポレイテッド 免疫調節化合物を用いたｃ型肝炎の治療または予防の方法

Also Published As

Publication number Publication date
NZ579570A (en) 2012-02-24
EP2120986A4 (en) 2010-04-07
CA2677749A1 (en) 2008-08-21
KR20090119897A (ko) 2009-11-20
US20100086622A1 (en) 2010-04-08
WO2008100458A2 (en) 2008-08-21
MX2009008641A (es) 2009-09-14
EP2120986A2 (en) 2009-11-25
UA96980C2 (ru) 2011-12-26
IL200364A0 (en) 2010-04-29
TW200845958A (en) 2008-12-01
CN101657210A (zh) 2010-02-24
JP2010518160A (ja) 2010-05-27
US7906486B2 (en) 2011-03-15
AR065338A1 (es) 2009-06-03
WO2008100458A3 (en) 2008-11-27
US20110117211A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
JP6518230B2 (ja) 炎症、自己免疫疾患、および疼痛を治療する方法
US11524015B2 (en) Methods for treating inflammation, autoimmune disorders and pain
US10568893B2 (en) Methods for treating inflammation, autoimmune disorders and pain
CN102065865B (zh) 多发性骨髓瘤治疗
WO1999034796A1 (en) Synergistic antitumor composition containing a naphthalensulphonic acid derivative
EP2185581B1 (en) Methods and compositions useful in the treatment of mucositis
JP2000514415A (ja) ソマトスタチン類似体およびラパマイシンの配合
EP2651414A1 (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
US7906486B2 (en) Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa
JP4927530B2 (ja) エポシロン誘導体および照射による増殖性疾患の処置
US20130096068A1 (en) Combination therapy with a proteasome inhibitor and a gallium complex
JP2009534383A (ja) 黒色腫の治療
WO2021133862A1 (en) Targeting the intrinsic apoptotic machinery in glioblastoma
TW202515897A (zh) 溶瘤肽及其用途
STUDIES POLISH HYPERBARIC RESEARCH 2 (75) 2021

Legal Events

Date Code Title Description
MK3 Application lapsed section 142(2)(c) - examination deferred under section 46 no request for examination